Cochrane Review Finds New Alzheimer’s Drugs Offer Trivial Benefits Despite High Costs
A leading international scientific review by Cochrane has cast serious doubt on the efficacy of a new wave of Alzheimer’s treatments, concluding they provide only trivial improvements to patients while carrying significant safety risks. The review analyzed 17 studies involving seven amyloid-beta-targeting monoclonal antibodies, including lecanemab and donanemab, which were approved in Australia in 2025 as the first new Alzheimer’s drugs in 25 years. Although these medications successfully clear amyloid plaque from the brain, lead author Francesco Nonino stated that this biological effect does not translate into meaningful clinical benefits regarding cognitive decline or dementia severity. The reviewers emphasized that observed effects fell well below thresholds for minimum clinically important difference. Furthermore, the drugs were associated with higher risks of brain swelling and micro-bleeds compared to placebos. While some experts criticized the inclusion of older, less effective medications in the analysis, the findings challenge the value proposition of these high-cost treatments. This development is particularly significant as dementia remains Australia’s leading cause of death, leaving patients and families seeking genuine therapeutic breakthroughs.
Wire timeline
Cochrane Review Finds New Alzheimer’s Drugs Offer Trivial Benefits Despite High Costs
A leading international scientific review by Cochrane has cast serious doubt on the efficacy of a new wave of Alzheimer’s treatments, concluding they provide only trivial improvements to patients while carrying significant safety risks. The review analyzed 17 studies involving seven amyloid-beta-targeting monoclonal antibodies, including lecanemab and donanemab, which were approved in Australia in 2025 as the first new Alzheimer’s drugs in 25 years. Although these medications successfully clear amyloid plaque from the brain, lead author Francesco Nonino stated that this biological effect does not translate into meaningful clinical benefits regarding cognitive decline or dementia severity. The reviewers emphasized that observed effects fell well below thresholds for minimum clinically important difference. Furthermore, the drugs were associated with higher risks of brain swelling and micro-bleeds compared to placebos. While some experts criticized the inclusion of older, less effective medications in the analysis, the findings challenge the value proposition of these high-cost treatments. This development is particularly significant as dementia remains Australia’s leading cause of death, leaving patients and families seeking genuine therapeutic breakthroughs.
theaustralian